Profitability guidance miss; dreams inching towards reality
18/03/24 -"DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by Immunodiagnostics (the firm’s major segment) was ..."
Pages
60
Language
English
Published on
18/03/24
You may also be interested by these reports :
26/04/24
Clariane reported 7.4% growth in its Q1 statutory and organic revenue, with the dynamism being witnessed in all the segments and regions. The ...
24/04/24
Getinge reported a mixed set of results, missing top-line estimates marginally but beating on profit and order intake. Investors cheered the latter, ...
23/04/24
We have factored the 2023 actual figures into our model ahead of the availability of the annual report and more detailed information. The difference ...
22/04/24
Sartorius Stedim reported softer-than-expected Q1 24 numbers, missing the consensus by 5.7%/3.4% on the top line/bottom line, respectively. The ...